Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 10, pp 1421–1428 | Cite as

Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

  • Takeshi Hara
  • Hisashi Tsurumi
  • Naoe Goto
  • Nobuhiro Kanemura
  • Takeshi Yoshikawa
  • Senji Kasahara
  • Toshiki Yamada
  • Michio Sawada
  • Hideko Goto
  • Kenji Fukuno
  • Jun-ichi Kitagawa
  • Ichiro Yasuda
  • Naoki Katsumura
  • Masao Takemura
  • Takeshi Takahashi
  • Tsuyoshi Takami
  • Hisataka Moriwaki
Original Paper

Abstract

Introduction

We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). Here, we investigated whether the role of sFas as a prognostic factor remains valid in the R-CHOP era.

Patients

We treated 132 patients with DLBCL between October 1995 and September 2002 (group A: without rituximab), and 75 between December 2002 and March 2007 (group B: with rituximab). The patients received eight cycles of CHOP or THP (tetrahydropyranyl-adriamycin)-COP before September 2002, and R-CHOP or R-THP-COP after October 2002. The distribution of patients according to the International Prognostic Index did not significantly differ between the groups.

Results

The 5-year overall survival (OS) rates for patients with sFas levels of ≥3.0 and <3.0 ng/ml in group A were 19.8 and 61.9% (P < 0.0001), whereas the 3-year OS rates in group B were 54.7 and 92.2% (P < 0.01), respectively. Multivariate analysis using the proportional hazards model revealed that sFas most significantly correlated with overall survival (P < 0.05).

Conclusion

Serum sFas is thus a useful tool for selecting the appropriate therapeutic strategy for DLBCL.

Keywords

Diffuse large B-cell lymphoma (DLBCL) Soluble Fas (sFas) Prognostic analysis Revised International Prognostic Index 

References

  1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511. doi:10.1038/35000501 CrossRefPubMedGoogle Scholar
  2. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762. doi:10.1126/science.7510905 CrossRefPubMedGoogle Scholar
  3. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
  4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242. doi:10.1056/NEJMoa011795 CrossRefPubMedGoogle Scholar
  5. Fisher RI, Shah P (2003) Current trends in large cell lymphoma. Leukemia 17:1948–1960. doi:10.1038/sj.leu.2403096 CrossRefPubMedGoogle Scholar
  6. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas Ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192. doi:10.1126/science.270.5239.1189 CrossRefPubMedGoogle Scholar
  7. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:1131–1137PubMedGoogle Scholar
  8. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64:257–261. doi:10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2 CrossRefPubMedGoogle Scholar
  9. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534. doi:10.1056/NEJM199708213370804 CrossRefPubMedGoogle Scholar
  10. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 109–236Google Scholar
  11. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S (2003) Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. J Clin Oncol 21:1255–1262. doi:10.1200/JCO.2003.01.117 CrossRefPubMedGoogle Scholar
  12. Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268. doi:10.1002/mpo.2950220410 CrossRefPubMedGoogle Scholar
  13. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295. doi:10.1056/NEJMoa031770 CrossRefPubMedGoogle Scholar
  14. Nagata S (1997) Apoptosis by death factor. Cell 88:355–365. doi:10.1016/S0092-8674(00)81874-7 CrossRefPubMedGoogle Scholar
  15. Nicolaides C, Dimou S, Pavlidisa N (1998) Prognostic factors in aggressive non-Hodgkin’s lymphomas. Oncologist 3:189–197PubMedGoogle Scholar
  16. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood 94:3541–3550PubMedGoogle Scholar
  17. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202–1210. doi:10.1182/blood.V97.5.1202 CrossRefPubMedGoogle Scholar
  18. Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U, Okabe-Kado J (2003) Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin’s lymphoma. Leukemia 17:196–202. doi:10.1038/sj.leu.2402699 CrossRefPubMedGoogle Scholar
  19. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G (1996) An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro. J Immunol 156:4622–4630PubMedGoogle Scholar
  20. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi:10.1034/j.1600-0609.2002.01654.x CrossRefPubMedGoogle Scholar
  21. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861. doi:10.1182/blood-2006-08-038257 CrossRefPubMedGoogle Scholar
  22. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429PubMedGoogle Scholar
  23. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75:1169–1178. doi:10.1016/0092-8674(93)90326-L CrossRefPubMedGoogle Scholar
  24. Takagi T, Oguro M (1987) (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154. doi:10.1007/BF00253970 CrossRefPubMedGoogle Scholar
  25. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402 CrossRefGoogle Scholar
  26. The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112–2135. doi:10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2 CrossRefGoogle Scholar
  27. Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi:10.1007/s00432-003-0508-9 CrossRefPubMedGoogle Scholar
  28. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114. doi:10.1002/hon.815 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Takeshi Hara
    • 1
  • Hisashi Tsurumi
    • 1
  • Naoe Goto
    • 1
  • Nobuhiro Kanemura
    • 1
  • Takeshi Yoshikawa
    • 2
  • Senji Kasahara
    • 1
  • Toshiki Yamada
    • 1
  • Michio Sawada
    • 3
  • Hideko Goto
    • 4
  • Kenji Fukuno
    • 3
  • Jun-ichi Kitagawa
    • 1
  • Ichiro Yasuda
    • 1
  • Naoki Katsumura
    • 1
  • Masao Takemura
    • 5
  • Takeshi Takahashi
    • 2
  • Tsuyoshi Takami
    • 6
  • Hisataka Moriwaki
    • 1
  1. 1.First Department of Internal MedicineGifu University Graduate School of MedicineGifuJapan
  2. 2.Division of HematologyGifu Municipal HospitalGifuJapan
  3. 3.Department of HematologyGifu Red-Cross HospitalGifuJapan
  4. 4.Department of Internal MedicineKisogawa Municipal HospitalIchinomiyaJapan
  5. 5.Department of Informative Clinical MedicineGifu University Graduate School of MedicineGifuJapan
  6. 6.Department of ImmunopathologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations